Newpath is a private venture capital investment fund focused on disruptive treatments and technologies in the life science space. We search for innovative approaches across diverse fields including but not limited to: pharmaceuticals, regenerative and personalized medicine, basic sciences, devices, drug discovery, cellular and gene therapies, robotics, AR/VR and AI. With each investment, Newpath seeks to optimize performance by aligning the interests of academic founders, management teams, and investor groups.